Show simple item record

dc.contributor.authorCarrington, P A
dc.contributor.authorAnderson, Heather
dc.contributor.authorHarris, Martin
dc.contributor.authorWalsh, S E
dc.contributor.authorHoughton, J B
dc.contributor.authorMorgenstern, Godfrey R
dc.date.accessioned2010-08-17T08:58:02Z
dc.date.available2010-08-17T08:58:02Z
dc.date.issued1990-07
dc.identifier.citationAutoimmune cytopenias in Castleman's disease. 1990, 94 (1):101-4 Am. J. Clin. Pathol.en
dc.identifier.issn0002-9173
dc.identifier.pmid2193504
dc.identifier.urihttp://hdl.handle.net/10541/109698
dc.description.abstractThe authors report a case of Castleman's disease in which the major clinical problems have been caused by severe thrombocytopenia and neutropenia. The cytopenias were caused by autoimmune destruction of mature cells as demonstrated by bone marrow findings and cell-specific antibody assays. There also was evidence of red cell autoantibody production but no overt hemolysis. The thrombocytopenia currently is controlled by intermittent vincristine, having proved refractory to steroids, splenectomy, and danazol and only partially responsive to high dose intravenous immunoglobulin. The neutropenia showed temporary improvement with immunoglobulin but has been resistant to all other therapy. This case provides further evidence for disordered immune regulation in Castleman's disease.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAgranulocytosis
dc.subject.meshAutoimmune Diseases
dc.subject.meshFluorescent Antibody Technique
dc.subject.meshGiant Lymph Node Hyperplasia
dc.subject.meshGranulocytes
dc.subject.meshHumans
dc.subject.meshImmunoenzyme Techniques
dc.subject.meshMale
dc.subject.meshNeutropenia
dc.subject.meshThrombocytopenia
dc.titleAutoimmune cytopenias in Castleman's disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, Hope Hospital, Salford, United Kingdom.en
dc.identifier.journalAmerican Journal of Clinical Pathologyen
html.description.abstractThe authors report a case of Castleman's disease in which the major clinical problems have been caused by severe thrombocytopenia and neutropenia. The cytopenias were caused by autoimmune destruction of mature cells as demonstrated by bone marrow findings and cell-specific antibody assays. There also was evidence of red cell autoantibody production but no overt hemolysis. The thrombocytopenia currently is controlled by intermittent vincristine, having proved refractory to steroids, splenectomy, and danazol and only partially responsive to high dose intravenous immunoglobulin. The neutropenia showed temporary improvement with immunoglobulin but has been resistant to all other therapy. This case provides further evidence for disordered immune regulation in Castleman's disease.


This item appears in the following Collection(s)

Show simple item record